Early effects of dexamethasone implant on macular morphology and visual function in patients with macular edema secondary to retinal vein occlusion

Ophthalmologica

Volumn 232, Issue 3, 2014, Pages 144-148

  Veritti, Daniele ^a,b   Macor, Sara ^a   Lanzetta, Paolo ^a,b  

^a UNIVERSITY OF UDINE   (Italy)

^b Istituto Europeo di Microchirurgia Oculare   (Italy)

Author keywords

Dexamethasone; Macular edema; Optical coherence tomography; Retinal vein occlusion

Indexed keywords

DEXAMETHASONE; DRUG IMPLANT; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; BEST CORRECTED VISUAL ACUITY; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; DRUG IMPLANT; ENDOPHTHALMITIS; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE ABNORMALITY; MACULAR EDEMA; MALE; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; RETINA DETACHMENT; RETINA MACULA LUTEA; RETINA TEAR; RETINA VEIN OCCLUSION; SPECTRAL DOMAIN OPTICAL COHERENCE TOMOGRAPHY; SYSTEMIC DISEASE; VISION; VISUAL ACUITY; COMPLICATION; DRUG EFFECTS; INTRAOCULAR PRESSURE; MIDDLE AGED; OPTICAL COHERENCE TOMOGRAPHY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETINA; RETINAL VEIN OCCLUSION; VERY ELDERLY; VITREOUS BODY;

AGED; AGED, 80 AND OVER; DEXAMETHASONE; DRUG IMPLANTS; FEMALE; GLUCOCORTICOIDS; HUMANS; INTRAOCULAR PRESSURE; MACULAR EDEMA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETINA; RETINAL VEIN OCCLUSION; TOMOGRAPHY, OPTICAL COHERENCE; VISUAL ACUITY; VITREOUS BODY;

EID: 84927924325     PISSN: 00303755     EISSN: 14230267     Source Type: Journal    
DOI: 10.1159/000366232     Document Type: Article

References (23)

1. Wong TY, Scott IU: Retinal-vein occlusion. N Engl J Med 2010; 363: 2135-2144.
2. Royal College of Ophthalmologists: Interim Guidelines for Management of Retinal Vein Occlusion. 2010. www.rcophth.ac.uk/core/core picker/download.asp?id=728 (accessed June 2014).
3. Hayreh SS: Occlusion of the central retinal vessels. Br J Ophthalmol 1965; 49: 626-645.
4. Hayreh SS: Retinal vein occlusion. Indian J Ophthalmol 1994; 42: 109-132.
5. Central Vein Occlusion Study Group: Baseline and early natural history report: the Central Vein Occlusion Study. Arch Ophthalmol 1993; 111: 1087-1095.
6. Haller JA, Bandello F, Belfort R Jr., Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jacques ML, Jiao J, Li XY, Whitcup SM: Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010; 117: 1134-1146.
7. Haller JA, Bandello F, Belfort R Jr., Blumenkranz MS, Gillies M, Heier J, Loewenstein A, Yoon YH, Jiao J, Li XY, Whitcup SM: Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion. Ophthalmology 2011; 118: 2453-2460.
8. Campochiaro PA, Hafiz G, Shah SM, Nguyen QD, Ying H, Do DV, Quinlan E, Zimmer-Galler I, Haller JA, Solomon SD, Sung JU, Hadi Y, Janjua KA, Jawed N, Choy DF, Arron JR: Ranibizumab for macular edema due to retinal vein occlusions: implication of VEGF as a critical stimulator. Mol Ther 2008; 16: 791-799.
9. Sarao V, Veritti D, Boscia F, Lanzetta P: Intravitreal steroids for the treatment of retinal diseases. ScientificWorldJournal 2014; 2014: 989501.
10. Yeh WS, Haller JA, Lanzetta P, Kuppermann BD, Wong TY, Mitchell P, Whitcup SM, Kowalski JW: Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant. Ophthalmology 2012; 119: 1190-1198.
11. Querques G, Lattanzio R, Querques L, Triolo G, Cascavilla ML, Cavallero E, Del Turco C, Casalino G, Bandello F: Impact of intravitreal dexamethasone implant (Ozurdex) on macular morphology and function. Retina 2014; 34: 330-341.
12. Joshi L, Yaganti S, Gemenetzi M, Lightman S, Lindfield D, Liolios V, Menezo V, Shao E, Taylor SR: Dexamethasone implants in retinal vein occlusion: 12-month clinical effectiveness using repeat injections as-needed. Br J Ophthalmol 2013; 97: 1040-1044.
13. Bezatis A, Spital G, Höhn F, Maier M, Clemens CR, Wachtlin J, Lehmann F, Hattenbach LO, Feltgen N, Meyer CH: Functional and anatomical results after a single intravitreal Ozurdex injection in retinal vein occlusion: a 6-month follow-up-the SOLO study. Acta Ophthalmol 2013; 91:e340-e347.
14. Moisseiev E, Goldstein M, Waisbourd M, Barak A, Loewenstein A: Long-term evaluation of patients treated with dexamethasone intravitreal implant for macular edema due to retinal vein occlusion. Eye 2013; 27: 65-71.
15. Querques L, Querques G, Lattanzio R, Gigante SR, Del Turco C, Corradetti G, Cascavilla ML, Bandello F: Repeated intravitreal dexamethasone implant (Ozurdex ® ) for retinal vein occlusion. Ophthalmologica 2013; 229: 21-25.
16. Charmandari E, Kino T, Ichijo T, Chrousos GP: Generalized glucocorticoid resistance: clinical aspects, molecular mechanisms and implications of a rare genetic disorder. J Clin Endocrinol Metab 2008; 93: 1563-1572.
17. Zhou J, Cidlowski JA: The human glucocorticoid receptor: one gene, multiple proteins and diverse responses. Steroids 2005; 70: 407-417.
18. Schaaf MJ, Cidlowski JA: Molecular mechanisms of glucocorticoid action and resistance. J Steroid Biochem Mol Biol 2002; 83: 37-48.
19. Uckermann O, Kutzera F, Wolf A, Pannicke T, Reichenbach A, Wiedemann P, Wolf S, Bringmann A: The glucocorticoid triamcinolone acetonide inhibits osmotic swelling of retinal glial cells via stimulation of endogenous adenosine signaling. J Pharmacol Exp Ther 2005; 315: 1036-1045.
20. Zhao M, Bousquet E, Valamanesh F, Farman N, Jeanny JC, Jaisser F, Behar-Cohen FF: Differential regulations of AQP4 and Kir4.1 by triamcinolone acetonide and dexamethasone in the healthy and inflamed retina. Invest Ophthalmol Vis Sci 2011; 52: 6340-6347.
21. Framme C, Wolf S, Wolf-Schnurrbusch U: Small dense particles within the neurosensory retinal layers observable by spectral domain optical coherence tomography in age-related macular degeneration. Invest Ophthalmol Vis Sci 2010; 51: 5965-5969.
22. Bolz M, Schmidt-Erfurth U, Deak G, Mylonas G, Kriechbaum K, Scholda C: Optical coherence tomographic hyperreflective foci: a morphologic sign of extravasation in diabetic macular edema. Ophthalmology 2009; 116: 914-920.
23. Framme C, Schweizer P, Imesch M, Wolf S, Wolf-Schnurrbusch U: Behavior of SD-OCTdetected hyperreflective foci in the retina of anti-VEGF-treated patients with diabetic macular edema. Invest Ophthalmol Vis Sci 2012; 53: 5814-5818.